Chaitra S. Ujjani, MD

Physician
Seattle Cancer Care Alliance
Clinical Associate Professor, Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Clinical expertise
Lymphomas and chronic lymphocytic leukemia
“Oncology is the epitome of understanding how to practice the art of medicine.”
— Dr. Ujjani
Why do you practice oncology?

At the age of 17, I knew that I was going to be a doctor. I have never once regretted that decision. As an oncologist, I find it satisfying to work with patients to achieve a common goal. The science behind different forms of cancer is also fascinating — I want to know what’s driving them. There’s a creativity to oncology right now, in trying to figure out how to bring new therapies together and how to integrate them with current treatment approaches. I’m invested in trying to understand that so I can improve outcomes for you. It’s this excitement that brings me to work every day.

Chaitra_Ujjani_Secondary.jpg
What do you want patients to know about working with you?

Oncology is an art in the sense that I can’t just look at the data and make a decision about what’s best for you. There are many nuances to consider, not only the biology of your disease but also you as the patient: your personal goals, your living situation, your fitness level and your age, just to name a few. When it comes to blood cancers, there are so many more treatment combinations available than there used to be, which is great, but it also means that the way forward isn’t simple. Together, we take in all of the information and decide on the best approach.

Provider background

Specialties and clinical expertise: Hematologic malignancies

Lymphomas and chronic lymphocytic leukemia

I am a board-certified medical oncologist who specializes in the treatment of lymphomas and chronic lymphocytic leukemia (CLL). These cancers affect white blood cells, which are responsible for fighting off infection. For more than a decade, I’ve designed and led multi-center clinical trials that test new drug combinations for treating these diseases, with the goals of more precisely targeting cancer while decreasing the intensity of side effects. I’m also interested in immunotherapy, how patients’ own immune cells can be extracted and engineered to attack their cancer. In addition to patient care and research, I am an active member of the Leukemia & Lymphoma Society, and I’ve presented my research at the annual conference of the American Society of Hematology.

Diseases treated

Education, experience and certifications
Undergraduate Degree
University of Alabama, Birmingham
Medical Degree
University of Alabama School of Medicine
Residency
Hospital of the University of Pennsylvania, Internal Medicine
Fellowship
Georgetown University Hospital, Hematology-Oncology
Board Certification
Oncology, 2011; Hematology, 2011, American Board of Internal Medicine
Languages
English
Awards
American Cancer Society Young Investigator Research Grant

Dr. Ujjani received the 2016 American Cancer Society Young Investigator Research Grant to support her clinical trial work testing new drug combinations in the treatment of relapsed follicular lymphoma.

Leukemia & Lymphoma Society Relentless for a Cure Award

This award honors excellence in patient education and research.

Research

Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
Immune Response to COVID-19 Vaccines in Patients with CLL/SLL
Complete title
Immune Response to COVID-19 Vaccines in Patients with CLL/SLL
Study ID:
NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Complete title
A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Study ID:
NCT02956382
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Complete title
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Publications

Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.

Press

SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.

COVID-19 Vaccines Are Entering Uncharted Immune Territory

SCCA's Chaitra Ujjani, MD, talked about the importance of cancer patients receiving the COVID-19 vaccine.

Are Covid-19 vaccines safe for cancer patients? Here is what cancer experts say

SCCA's Chaitra S. Ujjani, MD, spoke with CNN Health about COVID-19 vaccinations for patients with blood cancers and discussed how SCCA is conducting clinical trials for other cancer types including certain immune system and blood cancers

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.

Insurance

SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers